PSMAddition: An International Prospective Open-label,Randomized, Phase III Study comparing 177Lu-PSMA-617in combination with Standard of Care, versus Standard ofCare alone, in adult male patients with Metastatic HormoneSensitive Prostate Cancer (mHSP

Project: Research project

Project Details

Description

PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSP
StatusActive
Effective start/end date1/18/22 → 1/31/27

Funding

  • NOVARTIS PHARMACEUTICALS CORPORATION

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint